1. Home
  2. SII vs DYN Comparison

SII vs DYN Comparison

Compare SII & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sprott Inc.

SII

Sprott Inc.

HOLD

Current Price

$104.49

Market Cap

3.4B

Sector

Finance

ML Signal

HOLD

DYN

Dyne Therapeutics Inc.

HOLD

Current Price

$23.54

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SII
DYN
Founded
2008
1984
Country
Canada
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
3.9B
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
SII
DYN
Price
$104.49
$23.54
Analyst Decision
Hold
Strong Buy
Analyst Count
1
14
Target Price
$132.00
$37.00
AVG Volume (30 Days)
181.2K
2.4M
Earning Date
05-06-2026
05-04-2026
Dividend Yield
1.11%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$26.03
N/A
Revenue Next Year
$11.83
N/A
P/E Ratio
$63.42
N/A
Revenue Growth
N/A
N/A
52 Week Low
$61.94
$8.88
52 Week High
$169.63
$25.00

Technical Indicators

Market Signals
Indicator
SII
DYN
Relative Strength Index (RSI) 38.31 60.70
Support Level $103.64 $16.47
Resistance Level $120.13 $24.52
Average True Range (ATR) 3.97 1.40
MACD -0.15 -0.08
Stochastic Oscillator 15.75 63.43

Price Performance

Historical Comparison
SII
DYN

About SII Sprott Inc.

Sprott Inc is an alternative asset manager. The company has four reportable segments: Exchange Listed Products, which derives key revenue, and includes management services to the company's closed-end physical trusts and exchange-traded funds, both of which are actively traded on public securities exchanges; Managed equities segment provides asset management and sub-advisory services to the company's branded funds, fixed-term LPs and managed accounts; Private strategies which provide lending and streaming activities through limited partnership vehicles; and the Corporate segment which provides capital, balance sheet management and enterprise shared services to the company's subsidiaries. Geographically, it derives key revenue from Canada, followed by the United States.

About DYN Dyne Therapeutics Inc.

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Share on Social Networks: